Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $500K | $377K | $2.45M | $3.00M | $71.0K |
| Revenue growth | — | — | — | — | — | — | -24.6% | 550.4% | 22.1% | -97.6% |
| Gross profit | — | — | — | — | — | -$85.0K | — | — | — | — |
| Gross margin | — | — | — | — | — | -17.0% | — | — | — | — |
| Operating income | -$5.65M | -$8.03M | -$10.6M | -$14.3M | -$23.4M | -$54.4M | -$91.1M | -$68.8M | -$44.5M | -$21.8M |
| Operating margin | — | — | — | — | — | -10878.6% | -24161.0% | -2805.7% | -1485.4% | -30712.7% |
| Net income | -$5.65M | -$9.52M | -$18.0M | -$16.5M | -$34.3M | -$50.3M | -$89.0M | -$64.2M | $39.8M | $401K |
| Net margin | — | — | — | — | — | -10069.4% | -23602.9% | -2617.3% | 1328.6% | 564.8% |
| EPS (diluted) | -$0.44 | -$0.71 | -$0.81 | -$0.54 | -$0.72 | -$0.65 | -$15.03 | -$9.16 | $14.90 | -$5.63 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.45M | -$6.61M | -$8.79M | -$13.4M | -$21.9M | -$40.6M | -$71.0M | -$52.0M | -$33.6M | -$5.21M |
| Capital expenditures | $21.8K | $5.30K | $26.6K | $27.0K | $55.0K | $1.47M | $1.54M | $242K | $55.0K | $31.0K |
| Free cash flow | -$4.48M | -$6.61M | -$8.81M | -$13.4M | -$22.0M | -$42.1M | -$72.5M | -$52.3M | -$33.6M | -$5.24M |
| Share buybacks | — | — | — | $101K | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $586K | $1.54M | $8.22M | $6.22M | $17.3M | $77.3M | $39.7M | $19.6M | $1.19M | $1.54M |
| Total assets | $870K | $1.64M | $8.50M | $7.24M | $19.8M | $87.0M | $54.0M | $33.1M | $30.7M | $38.8M |
| Total liabilities | $1.19M | $4.49M | $11.0M | $11.9M | $20.3M | $7.56M | $43.0M | $57.1M | $37.7M | $16.5M |
| Shareholders' equity | -$319K | -$2.85M | -$2.31M | -$3.82M | $1.90M | $61.7M | -$9.68M | -$53.8M | -$2.50M | $34.0M |
| Retained earnings | -$7.70M | -$17.9M | -$37.0M | -$53.7M | -$88.3M | -$139M | -$228M | -$294M | -$255M | -$259M |
| Shares (wtd avg diluted) | 13.0M | 14.6M | 27.1M | 40.5M | 63.8M | 77.5M | 5.94M | 7.23M | 2.17M | 670K |
Every figure is extracted from PAVmed Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.